

Haematologica
HAEMATOL/2019/220475
Version 3

Variable global distribution of cell-of-origin from the ROBUST phase 3
study in diffuse large B-cell lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Thomas E. Witzig,
David W. Scott, Michele Spina, Randy D. Gascoyne, Lei Zhang,
Jacqueline Russo, Janet Kang, Jingshan Zhang, Yingyong Xu, and
Umberto Vitolo

Disclosures: G.S.N.: Consulting or advisory role with AbbVie, Bayer, Celgene, Janssen, Karyopharma, MorphoSys, Pharmacyclics, and Roche; research funding from Bayer, Celgene, Curis, MorphoSys, NanoString Technologies, and Roche. A.C.: Consulting or advisory role with Celgene and Janssen; speakers' bureau for Amgen, Celgene, Janssen, NanoString Technologies, Roche, and Teva T.E.W.: Consulting or advisory role with Celgene and Seattle Genetics – personally uncompensated; stock ownership in Valeant Pharmaceuticals International; research funding from Celgene, Novartis, Spectrum Pharmaceuticals, and Acerta Pharma D.W.S.: Consulting or advisory role with Celgene and Janssen; research funding from NanoString Technologies, Janssen, and Roche/Genentech; named inventor on a pending patent describing gene expression profiling in prognostication in classical Hodgkin lymphoma; as a member of LLMPP, potentially a named inventor on a pending patent on the use of gene expression profiling to assign cell-of-origin in diffuse large B-cell lymphoma; named inventor on a pending patent on the use of gene expression profiling to determine the proliferation signature in mantle cell lymphoma M.S.: Honoraria and research funding from Menarini; honoraria from Mundipharma International, Teva, Gilead Sciences, Janssen-Cilag, CTI, Servier, and Sandoz R.D.G.: Consulting for Roche/Genentech. Named inventor similar to D.W.S. above, but have transferred all rights to BCCA upon retirement. L.Z., J.R., J.K., J.Z., and Y.X.: Employment and stock ownership with Celgene U.V.: Consulting or advisory role with Roche and Janssen; honoraria from Celgene; speakers' bureau with Roche, Celgene, Janssen, Gilead Sciences, Takeda, Sandoz and Bristol-Myers Squibb; research funding from Roche and Celgene

Contributions: Designed the study: G.S.N., A.C., T.E.W., D.W.S., R.D.G., L.Z., J.R., U.V. Performed research: G.S.N., A.C., T.E.W., M.S., J.R., U.V. Collected, analyzed, managed, and/or interpreted data: All authors Performed statistical analysis: L.Z., J.R., J.K., J.Z., and Y.X. Critically reviewed and approved the final manuscript for submission: All authors